Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation-Reference-Cited by-同舟云学术

Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation

Published:2021-03-22 Issue:3 Volume:377 Page:370-384
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Lin Qingxiang,Qian Zhicheng,Jusko William J.,Mager Donald E.,Ma Wen Wee,Straubinger Robert M.^ORCID

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference62 articles.

1. Systems Pharmacological Analysis of Paclitaxel-Mediated Tumor Priming That Enhances Nanocarrier Deposition and Efficacy

2. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma

3. Pancreatic Cancer Chemoresistance to gemcitabine;Amrutkar;Cancers (Basel),2017

4. Affinity, intrinsic activity and drug interactions;Ariens;Pharmacol Rev,1957

5. Advances and challenges in targeting FGFR signalling in cancer

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness;Drug Resistance Updates;2024-03

2. Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single‐agent fibroblast growth factor receptor‐specific inhibitors in pancreatic cancer;British Journal of Pharmacology;2024-01-22

3. Highly Reproducible Quantitative Proteomics Analysis of Pancreatic Cancer Cells Reveals Proteome-Level Effects of a Novel Combination Drug Therapy That Induces Cancer Cell Death via Metabolic Remodeling and Activation of the Extrinsic Apoptosis Pathway;Journal of Proteome Research;2023-10-31

4. Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer;Molecular & Cellular Proteomics;2022-10

5. Lipocalin 2 may be a key factor regulating the chemosensitivity of pancreatic cancer to gemcitabine;Biochemistry and Biophysics Reports;2022-09